High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker.
1/5 보강
N6-methyladenosine (m6A) is an RNA modification involved in RNA processing and widely found in transcripts.
APA
Hara T, Meng S, et al. (2024). High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker.. Cancer science, 115(7), 2360-2370. https://doi.org/10.1111/cas.16152
MLA
Hara T, et al.. "High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker.." Cancer science, vol. 115, no. 7, 2024, pp. 2360-2370.
PMID
38659235
Abstract
N6-methyladenosine (m6A) is an RNA modification involved in RNA processing and widely found in transcripts. In cancer cells, m6A is upregulated, contributing to their malignant transformation. In this study, we analyzed gene expression and m6A modification in cancer tissues, ducts, and acinar cells derived from pancreatic cancer patients using MeRIP-seq. We found that dozens of RNAs highly modified by m6A were detected in cancer tissues compared with ducts and acinar cells. Among them, the m6A-activated mRNA TCEAL8 was observed, for the first time, as a potential marker gene in pancreatic cancer. Spatially resolved transcriptomic analysis showed that TCEAL8 was highly expressed in specific cells, and activation of cancer-related signaling pathways was observed relative to TCEAL8-negative cells. Furthermore, among TCEAL8-positive cells, the cells expressing the m6A-modifying enzyme gene METTL3 showed co-activation of Notch and mTOR signaling, also known to be involved in cancer metastasis. Overall, these results suggest that m6A-activated TCEAL8 is a novel marker gene involved in the malignant transformation of pancreatic cancer.
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- Nationwide Real-World Outcomes of Robot-Assisted Radical Prostatectomy Using the Hinotori Surgical Robot System in Japan.
- Enhanced release of ciliary extracellular vesicles suppresses cell migration and promotes cell aggregation.
- Cancer-Associated Thrombosis, With a Focus on Ischemic Heart Disease.
- Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial Carcinoma.
- Pathologic complete response to enfortumab vedotin plus pembrolizumab in node-positive urothelial carcinoma: a case report.